IP Library Granted Patent US 9,290,506
Granted Patent B2
US 9,290,506 · App. 14/593,688 · Granted Mar 22, 2016

Processes for preparing JAK inhibitors and related intermediate compounds

Inventors: Jiacheng Zhou (Newark, DE); David Meloni (Bear, DE); Yongchun Pan (Newark, DE); Mei Li (Newark, DE); Pingli Liu (Newark, DE); Brian W. Metcalf (Moraga, CA); Tai-Yuen Yue (Hockessin, DE)
Assignees: Incyte Corporation; Incyte Holdings Corporation
C07D487/04C07F7/10C07F7/1892
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,290,506
App. No.
14/593,688
Granted
Mar 22, 2016
Kind
B2
Abstract

The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.

Claims (8)

1. A process of preparing a composition comprising an enantiomeric excess of the (R)-enantiomer of a compound of Formula III′:

comprising:

(a) treating a composition comprising an enantiomeric excess of the (S)-enantiomer of a compound of Formula I″:

with a compound of Formula D-1′:

in the presence of cesium carbonate in acetonitrile under conditions sufficient to form the racemate of the compound of Formula I″;

(b) passing said composition comprising said racemate of said compound of Formula I″ through a chiral chromatography unit using a mobile phase and collecting a composition comprising an enantiomeric excess of the (R)-enantiomer of said compound of Formula I″; and

(c) reacting said compound of Formula I″ with boron trifluoride diethyl etherate, followed by aqueous ammonium hydroxide to form a composition comprising an enantiomeric excess of the (R)-enantiomer of said compound of Formula III′;

wherein * is a chiral carbon.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2015
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION
Reel/Frame 036803/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2015
From: ZHOU, JIACHENG; LIU, PINGLI; LIN, QIYAN; METCALF, BRIAN W.; MELONI, DAVID; PAN, YONGCHUN; XIA, MICHAEL; LI, MEI; YUE, TAI-YUEN; RODGERS, JAMES D.; WANG, HAISHENG
To: INCYTE CORPORATION
Reel/Frame 036739/0181 →
Continuity (4)
Division 13761830 · Feb 7, 2013
Division 12687623 · Jan 14, 2010
Provisional Application 61144991 · Jan 15, 2009
Related Publication 20150218174A1 · Aug 6, 2015